Related Experiment Video
Updated: Mar 18, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?
Mélody Mazon1, Delphine Masi2, Madeleine Carreau3,4
1CHU de Québec Research Center, 2705 Boulevard Laurier, RC-9800, Québec, QC G1V 4G2, Canada. melody.mazon@chudequebec.ulaval.ca.
Abstract:
Dickkopf-1 (DKK1) is a secreted Wnt/β-catenin pathway antagonist involved in embryogenesis. It was first described 25 years ago for its function in head induction and limb morphogenesis. Since then, this protein has been widely studied in the context of active Wnt/β-catenin signalling during cellular differentiation and development. Dysregulation of DKK1 has been associated with bone pathologies and has now emerged as a potential biomarker of cancer progression and prognosis for several types of malignancies. Reducing the amount of circulating DKK1 may reveal a simple and efficient strategy to limit or reverse cancer growth. This review will provide an overview of the role of Dickkopf-1 in cancer and explore its potential use as a biomarker and therapeutic target.
Insights
Dickkopf-1 (DKK1) protein is crucial in development and linked to bone diseases. This review explores DKK1
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Dickkopf-1 (DKK1) is a secreted antagonist of the Wnt/β-catenin pathway, essential for embryonic development.
- Dysregulation of DKK1 is implicated in bone pathologies.
- Emerging evidence links DKK1 to cancer progression and prognosis across various malignancies.
Purpose of the Study:
- To provide a comprehensive overview of Dickkopf-1's role in cancer.
- To explore the potential of DKK1 as a biomarker for cancer progression and prognosis.
- To evaluate DKK1 as a therapeutic target for cancer treatment.
Main Methods:
- Literature review of studies on Dickkopf-1.
- Analysis of DKK1's involvement in Wnt/β-catenin signaling.
- Examination of DKK1's association with different cancer types.
Main Results:
- DKK1 plays a significant role in embryogenesis and cellular differentiation.
- Elevated DKK1 levels are associated with adverse outcomes in several cancers.
- Targeting DKK1 may offer a therapeutic strategy to inhibit cancer growth.
Conclusions:
- Dickkopf-1 is a key regulator in development and disease.
- DKK1 holds promise as a biomarker for cancer prognosis.
- Inhibiting DKK1 presents a potential therapeutic avenue for cancer treatment.

